FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy

July 11, 2022 | Pratima Chowdary, M.D., F.R.C.Path., Royal Free Hospital, London, United Kingdom

RSS
12